Food and Drug Administration regulation and evaluation of vaccines
- PMID: 21502242
- DOI: 10.1542/peds.2010-1722E
Food and Drug Administration regulation and evaluation of vaccines
Abstract
The vaccine-approval process in the United States is regulated by the Center for Biologics Evaluation and Research of the US Food and Drug Administration. Throughout the life cycle of development, from preclinical studies to after licensure, vaccines are subject to rigorous testing and oversight. Manufacturers must adhere to good manufacturing practices and control procedures to ensure the quality of vaccines. As mandated by Title 21 of the Code of Regulations, licensed vaccines must meet stringent criteria for safety, efficacy, and potency.
Similar articles
-
Statistical, epidemiological, and risk-assessment approaches to evaluating safety of vaccines throughout the life cycle at the Food and Drug Administration.Pediatrics. 2011 May;127 Suppl 1:S31-8. doi: 10.1542/peds.2010-1722F. Epub 2011 Apr 18. Pediatrics. 2011. PMID: 21502249 Review.
-
Ensuring the optimal safety of licensed vaccines: a perspective of the vaccine research, development, and manufacturing companies.Pediatrics. 2011 May;127 Suppl 1:S16-22. doi: 10.1542/peds.2010-1722D. Epub 2011 Apr 18. Pediatrics. 2011. PMID: 21502248 Review.
-
Development and approval of vaccines in the United States.Isr J Med Sci. 1986 Mar-Apr;22(3-4):268-71. Isr J Med Sci. 1986. PMID: 3528047 Clinical Trial.
-
Bolstering the FDA's drug-safety authority.N Engl J Med. 2007 Nov 29;357(22):2217-9. doi: 10.1056/NEJMp078212. N Engl J Med. 2007. PMID: 18046024 No abstract available.
-
Assuring the quality, safety, and efficacy of DNA vaccines.Mol Biotechnol. 2001 Feb;17(2):143-9. doi: 10.1385/MB:17:2:143. Mol Biotechnol. 2001. PMID: 11395863 Review.
Cited by
-
The MMR Vaccine and Autism.Annu Rev Virol. 2019 Sep 29;6(1):585-600. doi: 10.1146/annurev-virology-092818-015515. Epub 2019 Apr 15. Annu Rev Virol. 2019. PMID: 30986133 Free PMC article. Review.
-
Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).Vaccine. 2015 Aug 26;33(36):4398-405. doi: 10.1016/j.vaccine.2015.07.035. Epub 2015 Jul 22. Vaccine. 2015. PMID: 26209838 Free PMC article. Review.
-
Immunosignatures can predict vaccine efficacy.Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18614-9. doi: 10.1073/pnas.1309390110. Epub 2013 Oct 28. Proc Natl Acad Sci U S A. 2013. PMID: 24167296 Free PMC article.
-
Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine.Hum Vaccin Immunother. 2015;11(6):1306-12. doi: 10.1080/21645515.2015.1009819. Hum Vaccin Immunother. 2015. PMID: 26086587 Free PMC article. Clinical Trial.
-
Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections.Front Immunol. 2020 Apr 9;11:592. doi: 10.3389/fimmu.2020.00592. eCollection 2020. Front Immunol. 2020. PMID: 32373111 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials